Vaccibody AS, a clinical-stage biopharmaceutical company focused on cancer vaccines, announced in a press release on November 5, 2019 the positive initial data from the ongoing VB N-01 (DIRECT-01) phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine.
These study results from the VB N-01 (DIRECT-01) phase I/IIa study were shared in a poster presentation titled, “VB10.NEO, an individualized neoepitope cancer vaccine, induces positive clinical responses in patients with locally advanced or metastatic solid tumours”, (Poster P424) on Saturday, November 9, 2019 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Agnete Fredriksen, President and Chief Scientific Officer of Vaccibody said:
“The data presented at this year’s SITC Annual Meeting showcase VB10.NEO and its ability to induce clinical responses including tumour shrinkage in a significant number of the first patients. We are very excited about sharing these clinical data and the striking correlation with neoepitope quality and immune responses.“